الفهرس 
Title: Studies on biodegradable nanoadjuvants for mucosal vaccine delivery
AbstractOnly 14 pages are availabe for public view
 |  | from | 212 |  |  |
| | | from | 212 | | |
Abstract
It was inevitable that attempts to develop local adjuvants from local components be undertaken due to the sever need of the national vaccine industry. To our knowledge, this was the first successful formulation of nanoadjuvants using components available in the local market or synthesized in the lab. Some of the adjuvants prepared were biodegradable, oil-based nanoemulsions and chicken yolk IgY, while others were resistant to degradability as in the case of nanoaluminum hydroxide. The physical characteristics were studied using high resolution electron microscopy and zeta potential analyzer. While the adjuvant effects of the use of these preparations was studied using a Newcastle disease model following preparation of inactivated experimental vaccine formulations. NDV was selected because it is one of the most important avian pathogens Results showed that some of the developed preparations were more effective than imported commercial products like Montanide ISA 71, Montanide Gel O1, and aluminum hydroxide RehydragelR VL. Protection percentages of up to 50% were achieved using a nanoemulsion delivered via mucosal surfaces, while protection percentage of nanoaluminum hydroxide preparation reached up to 100% following injection, compared to 90% in the case of Montanide ISA 71 and 90% in case of Rehydragel®VL at similar experimental conditions; when challenge with 106 ELD50/100ulthe local NDV genotype VIId was conducted 21 days post-immunization. In conclusion, the described results demonstrate that local adjuvants can be produced It also shows that it is possible to improve commercial vaccines by incorporating some additional components. More importantly, this research demonstrates that important steps were made towards the development of a local mucosal adjuvant (better than the commercial mucosal adjuvant tested in this experiment). Further studies are needed to achieve higher protection rates by the described mucosal adjuvant preparation. This research is considered an important milestone in the complete independence of the national vaccine industry